Abstract
Considering the success of direct-acting antivirals (DAAs) to treat hepatitis C (HCV) and the shortage of organs for heart transplantation (HT), we institutionalized clinical protocol of using HCV-exposed donors in selected waitlist candidates. Prior to advent of DAAs, donor HCV viremia predicted poor post-HT outcomes, including higher risk of coronary allograft vasculopathy (CAV). Using intracoronary ultrasound (ICUS) in patients acquiring post-HT HCV infection, we examined the risk of CAV in current era.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
